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Short-term Mechanical Circulatory Support with a Centrifugal Pump 
- Results of Peripheral Extracorporeal Membrane Oxygenator 
According to Clinical Situation 
Woo  Surng  Lee,  M.D.*,  Hyun  Keun  Chee,  M.D.*,  Meong  Gun  Song,  M.D.*,  Yo  Han  Kim,  M.D.*, 
Je  Kyoun  Shin,  M.D.*,  Jun  Seok  Kim,  M.D.*,  Song  Am  Lee,  M.D.*,  Jae  Joon  Hwang,  M.D.*
Background:  A peripheral extracorporeal membrane oxygenator (p-ECMO) has been developed to support patients 
who are dying due to a serious cardiopulmonary condition. This analysis was planned to define the clinical sit-
uation in which the patient benefits most from a p-ECMO. Material and Methods: Between June 2007 and Aug 
2009, a total of 41 adult patients used the p-ECMO. There were 23 males and 18 females (mean age 54.4±15.1 
years). All patients had very unstable vital signs with hypoxia and complex cardiac problems. We divided the pa-
tients into 4 groups. In the first group, a p-ECMO was used as a bridge to cardiac operation. In the second 
group, patients did not have the opportunity to undergo any cardiac procedures; nevertheless, they were treated 
with a p-ECMO. In the third group, patients mostly had difficulty in weaning from CPB (cardiopulmonary bypass) 
after cardiac operation. The fourth group suffered from many complications, such as pneumonia, bleeding, in-
fections, and LV dysfunction with underlying cardiac problems. All cannulations were performed by the Seldinger 
technique or cutting down the femoral vessel. A long venous cannula of DLP
Ⓡ (Medtronic Inc, Minneapolis, MN) 
or RMI
Ⓡ (Edwards Lifesciences LLC, Irvine, CA) was used together with a 17∼21 Fr arterial cannula and a 21 
Fr venous cannula. As a bypass pump, a Capiox emergency bypass system (EBS
Ⓡ; Terumo, Tokyo, Japan) was 
used. We attempted to maintain a flow rate of 2.4∼3.0 L/min/m
2 and an activated clotting time (ACT) of around 
180 seconds. Results: Nine patients survived by the use of the p-ECMO. Ten patients were weaned from a 
p-ECMO but they did not survive, and the remainder had no chance to be weaned from the p-ECMO. The best 
clinical situation to apply the p-ECMO was to use it as a bridge to cardiac operation and for weaning from CPB 
after cardiac operation. Conclusion: Various clinical results were derived by p-ECMO according to the clinical 
situation. For the best results, early adoption of the p-ECMO for anatomical correction appears important. 
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INTRODUCTION
Strikingly  rapid  development  in  the  techniques  of  car-
diothoracic  surgery  now  allows  aggressive  interventions  for 
patients  with  high  risks  for  whom  previously  only  con-
servative  management  could  be  applied.  However,  in  such 
cases,  cardiac  arrest  or  cardiogenic  shock  may  easily  occur. 
Proper  management  of  circulation  and  vital  signs  post-
operatively  is  crucial  to  determining  the  prognosis  and  out-
come  of  surgery. 
Often  proper  perfusion  and  vital  signs  cannot  be  managed 
by  a  sufficient  amount  of  medication  such  as  digitalis  or 
vasoconstrictors.  Even  an  intra-aortic  balloon  pump  (IABP) 
sometimes  may  not  be  able  to  improve  circulation  or  vital 
signs. Such an emergent condition may be handled by a ven-
tricular assist device (VAD) or extracorporeal membrane oxy-
genation  (ECMO).  However,  such  conventional  mechanical 
cardiopulmonary  support  devices  are  only  operated  by  car-
diothoracic  surgeons  or  by  a  perfusionist.  Also,  the  duration 
of preparation takes quite a bit of time. Thus, it is very diffi-
cult  to  apply  in  an  emergency  in  which  cardiopulmonary  re-
suscitation  is  performed.  Furthermore,  those  devices  have 
demonstrated  a  low  survival  rate,  regardless  of  their  ag-
gressive methods of management [1]. Postoperative complica-
tions  arising  from  using  a  cardiopulmonary  bypass  system 
(CPB)  include  postcardiotomy  cardiogenic  shock  (PCS), 
which  interrupts  weaning  from  the  CPB,  uncontrolled  hemor-
rhage  and  arrhythmia,  and  even  cardiac  arrest.  These  compli-
cations  may  develop  with  a  frequency  of  about  2∼8%  after 
open  cardiothoracic  surgery.  Thus,  it  has  been  suggested  that 
several  supportive  devices  be  developed,  which  may  assist  in 
weaning  from  CPB  postoperatively  [2]. 
Recent  supplementation  of  automated  percutaneous  car-
diopulmonary support (PCPS) has ameliorated management of 
life support in patients with cardiogenic shock, cardiac arrest, 
adult  respiratory  distress,  aspiration  burns,  or  drug-induced 
myocarditis  [3,4].  Peripheral  extracorporeal  membrane  oxy-
genation  (p-ECMO)  not  only  complements  the  weakness  of 
conventional  devices  but  also  warrants  bedside  procedure.  It 
results  in  faster  management  of  circulation  and  vital  signs 
than  the  conventional  method  does;  thus,  the  p-ECMO  has 
become  a  very  effective  device  for  managing  patients  with 
cardiac  arrest  or  cardiogenic  shock  in-hospital  [3,5]. 
This  study  investigates  the  usefulness  and  clinical  applica-
tion  of  the  p-ECMO,  analyzing  clinical  cases  in  which 
p-ECMO  was  applied  to  manage  conditions  and  complica-
tions  caused  by  cardiogenic  shock.
MATERIAL AND METHODS
From  June,  2007  to  October,  2009,  p-ECMO  was  used  for 
a  total  of  41  patients  who  showed  cardiogenic  shock  or  car-
diac  arrest,  and  their  medical  records  were  analyzed 
retrospectively.  For  the  p-ECMO,  an  emergent  bypass  system 
(CAPIOX  EBS;  Teramo  Inc,  Tokyo,  Japan)  was  used.  The 
patients were divided into 4 different groups (Table 1). Group 
A included patients to whom p-ECMO was applied right after 
undergoing  CPR  and  before  cardiotomy  due  to  cardiogenic 
shock  occurred  from  coronary,  valvular,  or  aortic  diseases. 
Group  B  included  patients  who  could  not  receive  cardiotomy 
because  of  clinical  deterioration  in  spite  of  applying 
p-ECMO.  Group  C  represented  patients  who  had  undergone 
cardiotomy  for  other  clinical  conditions,  and  p-ECMO  was 
applied  because  they  could  not  be  weaned  from  CPB.  Group 
D  consisted  of  patients  who  had  p-ECMO  but  were  not  can-
didates  of  open  cardiotomy  due  to  complicated  underlying 
cardiac  diseases. 
All  patients  exhibited  systol i c  b l o o d  p r e s s u r e  b e l o w  8 0  
mmHg  for  over  30  min  along  with  mental  changes,  oliguria, 
or  other  symptoms  and  signs  related  to  peripheral 
vasoconstriction.  They  did  not  respond  to  a  full  admin-
istration  of  inotropes  or  vasopressors.  Also,  blood  gas  analy-
sis  displayed  pO2  below  60  mmHg  despite  having  O2 f u l l y  
administered.  CPR  was  performed  for  all  patients  exhibiting 
cardiac  arrest  or  clinical  conditions  requiring  resuscitation. 
Most  patients  fit  into  the  diagnostic  criteria  for  cardiogenic 
shock, but afterward septic shock was observed in two cases. 
One  case  was  confirmed  in  which  hypovolemic  shock  oc-
curred  along  with  cardiogenic  shock.  For  groups  A,  B,  and 
D,  p-ECMO  was  applied  as  a  bedside  procedure,  whereas  in 
group  C,  it  was  performed  in  an  operating  room.  To  make  a 
percutaneous  route  for  p-ECMO,  Seldinger's  method  was 
generally  used.  However,  in  two  cases  Seldinger's  method 
had failed to obtain vascular access, so the femoral artery and Short-term Mechanical Circulatory Support with a Centrifugal Pump
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Table 1. Patients characteristics 
Group  A
(n=10)
Group  B
(n=14)
Group  C
(n=8)
Group  D
(n=9)
Total
(n=41)
Gender  male/female
Age  (mean,  year)
Age  ＞70  years
Hospital  day
Total  duration  of  p-ECMO  (mean,  hour)
Survived  by  use  of  p-ECMO
Weaned  from  p-ECMO,  but  not  survived
Expired  and  not  weaned  from  p-ECMO
IABP  applied
Heart  transplantation  after  management
Disease  name
Aorta  problem  (AD,  AAA  rupture)
Valve  problem
Coronary  problem  (STEMI,  NSTEMI)
Cardiomyopathy
Congenital  heart  problem  (ASD,  TOF)
Pulmonary  embolism
H e m o t h o r a x  w i t h  p u l m o n a r y  e d e m a
Septic  shock
Drug  intoxication
5/5
54.7±10
1
60.4±80.4
49.91±62.20
4
5
1
4
1
2
4
3
1
0
0
0
0
0
9/5
57.8±18.6
4
13.9±12.6
  64.11±122.01
1
0
13
4
7
1
4
1
1
0
0
0
0
5/3
53.8±23.0
2
22.4±10.8
105.78±81.85
2
3
3
2
1
2
3
0
1
2
0
0
0
0
4/5
61.7±16.4
3
 3 5 ±47.0
91.95±74.95
2
2
5
2
0
1
0
1
0
2
2
2
1
23/18
54.4±15.1
10
31.5±49.7
74.88±94.92
 9
10
22
12
11  (27%)
  9  (22%)
  7  (16%)
  4  (10%)
3  (8%)
2  (5%)
2  (5%)
2  (5%)
1  (2%)
Group  A=Patients  that  adopted  a  peripheral  ECMO  as  a  bridge  to  cardiac  operation;  Group  B=Patients  that  did  not  have  chance  to 
undergo  any  cardiac  procedures,  nevertheless  they  were  applied  to  peripheral  ECMO;  Group  C=Patients  that  mostly  had  difficulty i n  
being  weaned  from  CPB  (cardiopulmonary  bypass)  after  cardiac  operation;  Group  D=Patients  suffered  from  many  complications,  such 
as  pneumonia,  bleeding,  infections  and  LV  dysfunction.  AD=Aortic  dissection;  AAA=Abdominal  aortic  aneurysm;  STEMI=ST  ele-
vation  M;  NSTEMI=Non  ST  elevation  MI;  ASD=Atrial  septal  defect;  TOF=Tetralogy  of  fallot.
vein  were  dissected  and  exposed.  There  were  no  complica-
tions  associated  with  the  dissection  and  exposure  of  the  fem-
oral  vessels.  For  optimal  drainage,  the  first  21  Fr  percuta-
neous  venous  cannula  (Medtronic  Inc.,  Minnerapolis,  MN, 
USA or Edwards's Lifescience LLC, Irvine, CA) was inserted 
through the incurrent canal, reaching the right atrium. Then, a 
17 to 21 Fr percutaneous arterial cannula inserted at the fem-
oral artery was located at the common iliac artery for the in-
current  canal.  While  inserting  the  catheter,  auto-priming  for 
the  next  10  min  began  simultaneously.  5,000  IU  of  heparin 
was  administered  just  before  inserting  the  catheter,  then  3 
mg/Kg/min  was  injected  intravenously  along  with  the  main-
tenance  of  ACT  between  180  to  200  sec.  After  pumping  be-
gan,  the  blood  volume  was  maintained  between  2.4∼3.0 
L/min/m
2, and the volume was adjusted based on factors such 
as  vital  signs  and  use  of  inotropes.  In  the  cases  of  group  C, 
the  same  method  was  applied  to  achieve  vascular  access,  ex-
cept  that  the  cardiotomy  site  was  closed  after  obtaining 
access.  Weaning  from  the  p-ECMO  was  attempted  when 
gradual  reduction  of  blood  flow  did  not  provoke  any  symp-
toms  or  signs  of  cardiogenic  shock  without  increasing  doses 
of digitalis or of inotropes. As the catheter was taken out, the 
catheter  insertion  site  was  compressed  in  a  sterile  condition, 
until either hemorrhage or subcutaneous edema was no longer 
observed. Vascular suture was performed for the two cases in 
which vascular dissection was applied. Administration of hep-
arin  was  stopped  after  removing  the  cannula,  but  neutraliza-
tion  using  protamine  was  not  attempted. 
The  clinical  manifestation  and  study  result  of  applying 
p-ECMO  to  the  above  patients  were  analyzed.  For  the  stat-
istical  methods,  analyzing  the  sex,  age,  clinical  presentation, 
weaning  of  EBS  and  long-term  survival,  Statistical  Package Woo Surng Lee, et al
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for  the  Social Sciences  (SPSS version  13.0,  Chicago, Illinois, 
U S A )  w a s  u s e d .  A n a l y z i n g  t h e  r i s k  f a c t o r s ,  t h e  c o n t i n u o u s  
variable  was  examined  by  the  Mann-Whitney  U  test,  where 
the  non-continuous  variable  was  evaluated  by  Fisher’s  exact 
test using a Chi square test. A p-value under 0.05 represented 
statistical  significance.  The  standard  deviation  and  its  range 
w e r e  i n d i c a t e d  w h e n  n e c e s s a r y .             
RESULTS
T h e  m e a n  a g e  o f  p a t i e n t s  i n  t h i s  s t u d y  g r o u p  w a s  5 4 . 4 ± 
15.1  (19∼86),  in  which  23  male  patients  and  18  female  pa-
tients  were  included.  The  ages  of  each  group  were  54.7 
(±10.0)  for  A,  57.8  (±18.6)  for  B,  53.8  (±23.0)  for  C,  and 
61.7  (±  16.4)  for  D.  Distinguished  by  sex,  group  A  included 
5 males and 5 females, B included 9 males and 5 females; C 
included 5 males and 3 females; and D included 4 males and 
5  females.  Among  them,  a  total  of  10  patients  were  over  70 
years  old:  one  patient  in  group  A,  4  in  group  B,  2  in  group 
C,  and  3  in  group  D.  The  mean  number  of  days  of  hospital 
stay was 31.5 (±49.7). By each group, it was 60.4 (±80.4) in 
A, 13.9 (±12.6) in B, 22.4 (±10.8) in C, and 35.0 (±46.7) in 
D  (Table  1). 
The  underlying  diseases  of  the  patients  included  11  cases 
of  aortic  diseases,  such  as  aortic  dissection  and  rupture 
(27%);  9  cases  of  mitral  or  aortic  valvular  diseases  (22%);  7 
cases  of  acute  coronary  syndrome,  like  acute  myocardial  in-
farction  (16%);  4  cases  of  myocardial  diseases,  including  hy-
pertrophic cardiomyopathy (10%); 3 cases  of congenital heart 
diseases, such as atrial septal defect or TOF (8%); 2 cases of 
acute  pulmonary  embolism  (5%);  2  cases  of  massive  hemo-
thorax  and  pulmonary  edema  that  occurred  in  the  post-car-
diotomy  state;  2  cases  of  septic  shock  following  cardiogenic 
shock in patients with underlying coronary disease or valvular 
disease;  and  1  case  of  cardiogenic  shock  due  to  myocardial 
damage  induced  by  drug  overdose  (2%)  (Table  1). 
Operations  used  for  members  of  group  A  included  one  of 
ascending  aorta  and  aortic  valve  replacement;  one  of  ascend-
ing  and  descending  aorta  replacement;  three  of  coronary  by-
pass  surgery;  two  of  aortic  valve  replacement;  two  of  mitral 
valve  replacement;  and  one  of  cardiac  transplantation.  Failure 
of  weaning  from  p-ECMO,  observed  in  group  C,  was  due  to 
low  cardiac  output,  shown  in  5  cases,  and  diffuse  hemor-
rhage,  exhibited  in  3  cases. 
41  patients  with  cardiogenic  shock,  who  had  underlying 
heart  diseases,  underwent  p-ECMO.  The  average  of  the  total 
hours  of  operation  was  74.88  (±94.92),  and  for  each  group, 
−49.91  (±62.20)  in  group  A;  64.11  (±122.01)  in  group  B; 
105.78  (±81.85)  in  group  C;  and  91.95  (±74.95)  in  group  D 
(Table 1). Statistical significance based on the hours of oper-
ation  was  not  observed  (p=0.71).  19  out  of  41  patients  were 
able  to  be  weaned  from  the  p-ECMO  (46.3%).  9  patients 
demonstrated  long-term  survival  (21.9%).  10  patients  suc-
ceeded  in  being  weaned  from  p-ECMO  but  did  not  survive 
(24.3%).  The  patients  who  showed  long-term  survival  in 
group  A  included  one  case  of  aortic  valvuloplasty  due  to  se-
vere  aortic  regurgitation;  two  cases  of  coronary  artery  bypass 
graft and CABG due to acute myocardial infarction; one case 
of  ascending  aorta  replacement,  and  aortic  valvuloplasty  due 
to ascending aortic dissection, aortic regurgitation and cardiac 
tamponade.  In  group  B,  there  was  one  case  of  cardiogenic 
shock  and  severe  pulmonary  edema  due  to  idiopathic 
cardiomyopathy.  In  group  C,  there  were  one  case  of  post-
operative low cardiac output syndrome due to ventricular sep-
tal  defect  and  Eisenmenger’s  syndrome  and  one  case  of 
Bentall’s  operation.  Group  D  included  a  case  that  had  re-
ceived  a  coronary  arytery  bypass  graft  and  succeeded  in  be-
ing  weaned  from  p-ECMO,  but  developed  hemothorax,  coro-
nary  hypoperfusion,  and  acute  respiratory  distress  syndrome 
(ARDS)  while  receiving  postoperative  care  in  the  ardiac  care 
unit  (Table  2).
Furthermore,  there  were  a  total  of  10  cases  that  were  suc-
cessfully weaned from p-ECMO but expired from unfavorable 
underlying cardiac disease. In group A, there were five cases: 
one  ascending  aorta  replacement  due  to  ascending  aortic  dis-
section,  one  cardiac  transplantation  due  to  dilated  cardiomy-
opathy, one removal of pulmonary embolus due to acute pul-
monary  embolism  that  occurred  after  total  knee  replacement, 
and  two  coronary  artery  bypass  grafts  due  to  acute  my-
ocardial  infarction  and  ischemic  heart  disease.  In  group  C, 
there  were  one  case  of  aortic  valvular  replacement,  one  as-
cending  aorta  replacement  and  aortic  valvuloplasty,  and  one 
cardiogenic  shock  that  occurred  during  re-operation  of  a  mi-
tral  valvular  replacement  due  to  postoperative  hemorrhage.  In Short-term Mechanical Circulatory Support with a Centrifugal Pump
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Table 2. Patients characteristics survived by use of peripheral 
ECMO 
Disease  and  clinical  course  No  (9)
ARDS  due  to  severe  hemothorax  after  cardiac
 o p e r a t i o n  
Post  OP  weaning  failure  after  ASD  closure  and 
  Eisenmenger’s  syn. 
Post  OP  weaning  failure  after  AVR  and  Bentall  OP 
Cardiogenic  shock  due  to  AR→p-ECMO→AVP 
Cardiogenic  shock  with  pulmonary  edema  due  to 
 I C M P  
Wide  QRS  VT  and  cardiac  muscle  injury  after  drug 
  intoxication 
NSTEMI  with  cardiogenic  shock→p-ECMO→CABG
STEMI  with  cardiogenic  shock→p-ECMO→CABG
AD  with  AR  &  cardiac  tamponade→p-ECMO→ 
 A G I  &  A V P  
Total
1
1
1
1
1
1
1
1
1
9
ARDS=Acute  respiratory  distress  syndrome;  ASD=Atrial  septal 
defect;  AVR=Aortic  valve  replacement;  p-ECMO=Peripheral 
ECMO;  AVP=Aortic  valvulopasty;  VT=Ventricular  tachycardia; 
AR=Aortic  regurgitation;  ICMP=Idiopathic  cardiomyopathy; 
NSTEMI=Non  ST  elevation  MI;  STEMI=ST  elevation  MI; 
AD=Aortic  dissection;  AGI=Aorta  graft  interposition.
Table 3. Patients characteristics weaned from peripheral ECMO, 
but not survived 
Disease  and  clinical  course  No  (10) 
CPR→p-ECMO→AD  (type  A)  OP→weaning 
Post  OP  weaning  failure  after  AVR→p-ECMO→
  weaning 
CPR→Aorta  graft  interposition  &  AVP→p-ECMO→
  weaning 
CPR  due  to  DCMP→p-ECMO→weaning→
  Heart  transplantation 
MVR→Post  OP  bleeding→Bleeding  control  OP→ 
 p - E C M O →weaning 
Pulmonary  embolism  after  TKR→p-ECMO→
  Embolectomy  with  CPB→weaning 
Cardiogenic  shock  in  malignant  urothelial  tumor→
 p - E C M O →weaning 
Cardiogenic  shock  due  to  MI→p-ECMO→CABG→
  weaning 
AVR→Cardiac  arrest    &  Pul.  edema  after  IABP
 r e m o v e →p-ECMO→weaning 
Cardiogenic  shock  due  to  IHD→p-ECMO→CABG→
  weaning 
Total
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
10
p-ECMO=Peripheral  ECMO;  AD=Aortic  dissection;  AVR=Aor-
tic  valve  replacement;  AVP=Aortic  valvulopasty;  DCMP=Dila-
ted  cardiomyopathy;  MVR=Mitral  valve  replacement;  TKR=To-
tal  knee  replacement;  MI=Myocardial  infarction;  CABG=Coro-
nary  artery  bypass  graft;  IHD=Ischemic  heart  disease. 
group D was observed one case of cardiogenic shock that oc-
curred  in  a  patient  with  atherosclerotic  coronary  disease  and 
ureteroepithelioma,  and  one  of  pulmonary  edema  that  oc-
curred  after  aortic  valvular  replacement  (Table  3).
The major cause of death was due to multiple organ failure 
due  to  irreversible  cardiac  damage  resulting  low  cardiac  out-
put  syndrome  and  cardiac  failure.  In  addition,  two  cases  of 
sepsis  were  confirmed  in  the  follow-up  lab  tests.  IABP  was 
applied  to  a  total  of  12  cases  (29.2%).  Moreover,  3  cases 
(7.3%) that simultaneously developed acute renal failure were 
applied  continuous  renal  replacement  therapy  (CCRT). 
Cardiac  transplantation  was  performed  in  two  cases  after 
p-ECMO  (4.8%).  A  long-term  follow-up  revealed  the  patient 
with  DCMP  in  group  A  had  expired,  receiving  medical  care 
in  an  outpatient  department.  On  the  other  hand,  the  DCMP 
patient in group C is currently being observed successfully in 
the  outpatient  department. 
Sex,  days  of  hospital  stay,  and  application  of  IABP  were 
not  statistical  factors  affecting  survival  rate  or  weaning  from 
p-ECMO.  However,  age  over  70  years  increased  mortality 
and  interfered  with  weaning  from  p-ECMO  (p=0.037).  The 
survival rate of 41 patients was 21.9% (n=9), and the rate of 
weaning  was  46.3%  (n=19).  Group  A,  in  which  p-ECMO 
was  used  preoperatively  to  correct  the  underlying  heart  con-
dition,  demonstrated  a  higher  survival  rate  (n=4,  40%)  and 
weaning  rate  (n=9,  90%)  than  the  other  groups.  Group  B, 
which was indicated to receive surgical treatment but it could 
not be attempted, exhibited the lowest survival rate (n=1, 7%) 
and  weaning  rate  (n=1,  7%).  Also,  group  C,  in  which 
p-ECMO  was  applied  post-cardiotomy  to  help  wean  from 
CPB,  showed  a  survival  rate  of  25%  (n=2)  and  a  weaning 
rate  of  62.5%  (n=5).  Group  D  displayed  a  survival  rate  of 
22.2%  (n=2)  and  a  weaning  rate  of  44.4%  (n=4). 
DISCUSSION
I n  t h e  e a r l y  1 9 7 0 ’ s ,  e x t r a c o r p oreal  life  support  (ECLS)  us-Woo Surng Lee, et al
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ing  extracorporeal  membrane  oxygenation  (ECMO)  was 
introduced.  A  large  number  of  patients  could  receive  ex-
tensive  supportive  care,  and  it  is  currently  known  to  be  the 
fastest  and  most  cost-effective  method  of  respiratory  support 
for  both  adults  and  children  [6].  Furthermore,  the  persistent 
efforts  of  cardiothoracic  surgeons  has  resulted  in  a  rapid  de-
velopment in cardiothoracic surgical techniques, allowing sur-
gical  treatment  for  diseases  previously  considered  contra-
indications  for  cardiotomy.  Recently,  even  patients  exhibiting 
cardiogenic shock or cardiac arrest are considered eligible for 
open  cardiotomy.  Such  patients  whose  condition  had  not  im-
proved  by  conventional  cardiopulmonary  resuscitation  could 
benefit  from  percutaneous  cardiopulmonary  support  (PCPS), 
which  helps  proper  perfusion  in  vital  organs,  such  as  the 
brain  or  kidneys.  Recent  studies  demonstrate  that  non-post-
cardiotomy cardiopulmonary failure may receive support from 
ECLS,  leading  to  a  survival  rate  of  40∼50%,  but  post-
cardiotomy  shock  only  presents  a  survival  rate  of  20∼36% 
despite application of ECLS. Thus, further study on the appli-
cation  of  ECLS  is  necessary  [2,7,8]. 
The most important factor in either ECLS or PCPS applied 
to  patients  with  unstable  cardiopulmonary  conditions  is  the 
membrane  oxygenator  of  which  the  ECMO  system  is 
composed. Development of bioengineering for oxygentors has 
increased  the  survival  of  patients  with  cardiopulmonary  fail-
ure  and  the  uses  of  ECLS  or  PCPS,  greatly  valuable  to  car-
diothoracic  surgeons  [9].  The  improvement  of  PCPS  has  en-
abled  the  maintenance  of  the  blood  supply  just  adequate  for 
perfusion to vital organs, and it has decreased the myocardial 
oxygen  demand.  Several  studies  have  reported  that  car-
diothoracic  surgery  successfully  carried  out  in  very  unstable 
cardiac  conditions  [10,11].
Such  PCPS  nowadays  was  indicated  to  unresponsive  to 
conventional  cardiopulmonary  resuscitation  [5].  This  is  found 
to  be  particularly  useful  in  patients  who  require  PCI  due  to 
ischemic heart disease but in whom cardiogenic shock or car-
diac  arrest  occurred.  Previously,  a  large  number  of  patients 
with  ischemic heart diseases, such as  coronary  artery  disease, 
had expired before an appropriate intervention, like PCI. Even 
when  re-perfusion  was  achieved,  very  severe  complications, 
damage to vital organs, and disturbances in consciousness had 
resulted  in  poor  prognosis.  However,  an  aggressive  approach 
by PCPS has been noted, for which not only the survival rate 
has  been  increased,  but  also  the  damage  to  vital  organ  has 
been  minimized.  Up-to-date  research  on  the  application  of 
PCPS  in  PCI  or  CABG  has  shown  a  25∼76%  of  success 
r a t e  [ 1 2 - 1 5 ] .  T h e  s t u d y  d o n e  i n  K o r e a  b y  R h e e ,  I l  i n  2 0 0 6  
r e p o r t e d  a  5 5 %  s u c c e s s  r a t e  [ 1 6 ] .  Such  reports  on  the  effi-
cacy  of  PCPS  have  a  large  deviation  in  the  success  rate. 
Such a deviation resulted from the study design of the patient 
group, and the timing of application and techniques related to 
operation and maintenance of PCPS, which differed in among 
v a r io u s  c e n te r s  [ 1 7 ] .  O u r  s t u d y  r e s u l t s  s h o w  a  l o w e r  s u r v iv a l 
rate  and  weaning  rate  than  studies  carried  out  in  other 
centers. It seems that setting the patient group exhibiting car-
diogenic shock or cardiac arrest as the study target  would be 
the  most  determinant  factor  affecting  the  study  results.  Also, 
p-ECMO  may  play  a  role  in  enabling  surgical  treatment  for 
those  with  very  unstable  vital  conditions.  However,  it  still 
does  have  a  limited  effect  on  advanced  cardiac  diseases. 
Nevertheless,  if  p-ECMO  were  applied  sooner  than  expected 
in spite of extremely unstable vital conditions, such as cardio-
genic  shock,  p-ECMO  would  be  an  optimal  intermediate, 
which  may  serve  as  a  bridge  to  surgical  treatment. 
Furthermore,  it  may  be  another  treatment  option  for  stabiliz-
ing  the  fluctuating  cardiopulmonary  status  postcardiotomy. 
In this study EBS
Ⓡ (CAPIOX: Terumo Inc., Tokyo, Japan) 
was used as p-ECMO. This extracorporeal membrane oxygen-
a t o r  h a s  a  s i m i l a r  s t r u c t u r e   and  disposition  to  the  conven-
tional  extracorporeal  membrane  oxygenator  used  in  cardio-
tomy.  However,  compared  to  CPB,  EBS  presents  several 
advantages.  It  utilizes    smaller  amounts  of  anticoagulants.  Its 
lifespan  is  improved.  Also,  it i s  o p e r a t e d  a s  a  b e d s id e  p r o c e -
dure;  it  is  very  mobile,  allowing  a  convenient  and  easy  ap-
proach  in  emergency  department  or  intensive  care  unit. 
Moreover, autopriming is  feasible, which brings high accessi-
bility, only requiring little knowledge or grasp of the machine 
and  anatomic  structure.  Therefore,  the  disadvantage  of  pri-
ming,  such  as  taking  more  than  30  min  and  operation  only 
by cardiothoracic surgeon or trained extracorporeal membrane 
perfusionist,  can  be  resolved.  The  blood  volume  required  for 
priming is only 470 cc, giving the least hemodynamic burden 
on  the  patient.  The  small  and  handy  structure  of  the  catheter 
may  reduce  operative  error,  and  its  structure  is  designed  to Short-term Mechanical Circulatory Support with a Centrifugal Pump
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easily  remove  air  that  enters  the  circuit.  Also,  if  the  vascular 
condition  is  optimal,  Seldinger’s  method  can  be  applied  for 
most cases. Even patients with hemodynamic instability, such 
as  cardiogenic  shock  and  cardiac  arrest,  can  benefit  from 
prompt  manipulation,  which  may  help  to  stabilize  vital  signs 
and to achieve hemodynamic stability. Such manipulation can 
s e r v e  a s  a  t o o l  u t i li z e d  f o r  e m e r g e n t s i t u a t io n s  a n d  lo n g - t e r m  
management out of the operating room [3,18]. In spite of the 
m a n y  a d v a n t a g e s  p r e s e n t e d  b y  t h e  E B S  s y s t e m ,  a  f e w  d i s -
advantages  are  observed.  The  membranous  oxygenator  adopts 
a  microporous  oxygenating  method,  leading  to  frequent  plas-
ma  leakage.  Also,  adequate  administration  of  anticoagulants 
including  heparin  could  not  completely  prevent  thrombus  in 
the  oxygenator,  and  the  straight  type  of  pump  used  in  the 
oxygenator even aggravates the formation of thrombus, result-
ing in a short lifespan of 2∼3 days. Persistent administration 
of  heparin  increases  the  risk  of  developing  cerebral  hemor-
rhage  or  a  bleeding  tendency.  Pulmonary  hypertension  devel-
oped  postoperatively  may  lead  to  pulmonary  hemorrhage.  All 
such  disadvantages  augment  the  postoperative  mortality  rate; 
therefore,  attentive  management  is  required  [8].  Recent  ad-
vancement  of  PCPS  includes  application  of  diffusion  mem-
brane composed of polymethyl pentene (PMP). It supplements 
the  inadequacy  of  EBS,  and  some  reports  indicate  better  re-
sults  than  EBS  [9].  PMP  allows  fluent  blood  flow  through  a 
kit  coated  with  albumin-heparin,  and  polymerization  of  albu-
min-heparin  on  the  catheter  does  not  wipe  out  the  coating. 
Therefore,  it  can  be  considered  a  biocompatible  model,  toler-
ating  long-term  use  of  at  least  14  days.  Other  advantages  in-
clude:  a  lower  rate  of  occurrence  of  hemolysis  due  to  the 
narrow  range  of  pressure  drop  and  amenable  control  of  body 
temperature  by  the  heat  exchanger,  allowing  application  even 
on  hypothermic  patients  [9].  In  this  study,  the  average  dura-
tion  of  use  of  p-ECMO  was  74.88  hours,  about  3.12  days.  8 
out  of  41  patients  developed  thrombus,  which  troubled  the 
oxygenator,  requiring  exchange  of  the  oxygenator.  2  out  of 
those  8  patients  had  to  exchange  the  oxygenator  one  more 
time  later  in  the  course. 
Vanier et al. [19] reported positive results from performing 
PCI on patients of high risk ischemic heart disease, who were 
already  inserted  with  a  PCPS.  Especially  in  those  presenting 
technical  difficulties  due  to  a  diseased  lesion  in  the  coronary 
artery  or  the  artery  itself  exhibiting  a  steep  angle  of  ap-
proach,  p-ECMO  was  inserted  before  performing  PCI.  They 
could be weaned from p-ECMO after the procedure. 3 of the 
15  patients  studied  expired  from  cardiac  problems  Thus, 
PCPS  can  support  PCI  in  high-risk  patients  who  are 
inoperable.  Also,  Burkle  et  al.  [20]  reported  the  success  of 
PCI  in  5  cases  of  high-risk  patients  with  severe  left  ven-
tricular  failure,  severe  co-morbid  disease,  or  difficulty  receiv-
ing  CABG,  of  which  PCPS  was  utilized  prior  to  PCI.  Thus, 
prior  utilization  of  PCPS  is  suggested  when  performing  PCI. 
The complications associated with use of PCPS include hem-
orrhage,  ischemia  of  the  lower  extremities,  renal  failure,  in-
fection,  or  multiple  organ  failure.  Such  complications  may 
differ greatly with a prolonged duration in maintenance of the 
machine, skill of the operator, patient condition, and improve-
ment  before  and  after  p-ECMO  [15,21]. 
Reichman  et  al.  [12]  reported  that  out  of  38  cardiac  arrest 
cases  in  which  PCPS  was  used  due  to  acute  myocardial  in-
farction,  7  survivors  received  CABG,  and  only  3  were  re-
ported  to  have  survived  long-term  Early  reports  by 
Matsuwaka et al. [13] and Suarez et al. [14] demonstrated the 
supportive  role  of  PCPS  in  cardiogenic  shock  due  to  acute 
cardiovascular  diseases.  Despite  the  low  survival  rate  in  the 
early  reports,  a  gradual  accumulation  in  clinical  reports  fol-
lowed an increase in survival rates, elicited by improved skill 
of  the  operator  and  advancement  of  PCPS.  In  regard  to  the 
broad gap in the survival rate among different centers, it will 
be  necessary  to  carry  out  a  multicenter  study  on  the  use  of 
PCPS  in  order  to  impose  specific  guidelines  for  use. 
However, the most important reason for having a large gap in 
the  survival  rate  results  is  probably  due  to  variations  in  the 
composition  of  the  patient  groups  [17].
This  study  indicated  that  only  19  out  of  41  patients 
(46.3%) were able to be weaned from p-ECMO, which is not 
much  better  than  other  studies.  Also,  only  a  total  of  9  pa-
tients  (21.9%)  showed  long-term  survival.  This  is  probably 
due  to  setting  up  a  study  group  composed  of  patients  with 
very  unstable  hemodynamics,  such  as  cardiogenic  shock  or 
cardiac arrest.  Our study also  included  patients  not only with 
coronary  heart  disease  but  also  aortic  diseases,  valvular  dis-
eases,  cardiomyopathy,  and  other  diseases  that  were  excluded 
in  other  studies.  This  might  have  affected  the  study  result  of Woo Surng Lee, et al
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the  survival  rate.  Hill  et  al.  [22]  reported  that  mortality  in-
creased  such  that  the  point  of  applying  PCPS  would  move 
further  from  the  point  of  occurrence  of  cardiogenic  shock  or 
cardiac  arrest.  Hence,  we  made  an  effort  to  reduce  the  dura-
tion  between  the  point  of  shock  and  PCPS  application,  by 
means of bedside procedure. When vital signs were relatively 
stabilized,  surgical  treatment  for  their  underlying  cardiac  dis-
eases  were  promptly  provided  to  patients  as  needed.  IABP, 
thought  to  be  helpful  in  patients  for  surgical  correction  as 
well as postoperative recovery, was readily used. For patients 
exhibiting signs  and  symptoms  of acute renal failure, such as 
oliguria,  CCRT  was  utilized  (n=3,  7.3%).  On  the  other  hand, 
because  blood  flow  created  by  PCPS  opposes  the  normal 
physiologic  blood  flow,  such  flow  can  become  a  factor  in-
creasing the afterload of the  left ventricle; consequently, ven-
tricular  enlargement  and  myocardial damage  may be  induced. 
Unless decompression of the left atrium is achieved, recovery 
of the left ventricle may be hindered [23]. If a better clinical 
manifestation  is  expected,  aggressive  use  of  IABP  combined 
w i t h  u s e  o f  P C P S  s h o u l d  b e  c o nsidered  for  recovery  of  car-
diac  function  [24]. 
Usually  the  vascular  connection  for  p-ECMO  is  veno-arte-
rial  (V-A  ECMO)  or  veno-venous  (V-V  ECMO),  and  in  our 
study,  V-A  p-ECMO  was  used  for  all  cases.  For  most  cases 
a  venous  catheter  can  be  inserted  into  the  internal  jugular 
vein,  right  atrium,  or  femoral  vein,  and  an  arterial  catheter 
can  be  inserted  into  the  right  carotid  artery,  axillary  artery, 
femoral artery, or aorta. V-A p-ECMO can help gas exchange 
and  cardiac  output,  whereas  V-V  p-ECMO  can  only  support 
gas  exchange  [25].  Shown  in  our  study,  V-A  p-ECMO  can 
aid  cardiac  function.  It  also  exhibits  the  advantage  of  rela-
tively  easy  access  through  the  carotid  artery  in  both  adults 
and  infants.  Nonetheless,  Ligation  of  the  catotid  artery  is 
sometimes  necessary  during  this  procedure  and  it  has  high 
risk  of  developing  cerebrovascular  complications.  Blood  flow 
to the entire body cannot be sent in a pulsatile mode. If pul-
monary  function  is  severely  deteriorated,  the  oxygen  satu-
ration of the blood running from the left ventricle to the cor-
onary artery would be much lower than the oxygen saturation 
obtained from peripheral blood gas analysis. This might cause 
cardiac  failure  due  to  inadequate  perfusion  to  the  myocar-
dium.  If  respiratory  support  is  the  sole  purpose  of  using 
PCPS  and  if  there  is  no  abnormality  observed  in  cardiac 
function,  V-V  p-ECMO  can  be  applied  [26].  Furthermore,  if 
typical  V-A  p-ECMO  cannot  provide  adequate  perfusion  to 
the  myocardium,  a  change  to  or  combined  use  with  V-V 
p-ECMO  may  increase  not  only  oxygen  saturation  of  the  en-
tire  body  but  also  that  of  the  myocardium  [27]. 
CONCLUSION
Despite  using  a  retrospective  study  with  a  small  sample 
size, an aggressive approach to surgical treatment, an invasive 
procedure using PCPS is indispensable for patients with lethal 
conditions,  including  cardiogenic  shock  or  cardiac  arrest.  If 
p-ECMO is applied in advance to patients exhibiting hemody-
namic  instability  requiring  cardiopulmonary  resuscitation,  it 
may  function  as  an  excellent  intermediate  stabilizing  con-
dition preoperatively. Also, it could work as another treatment 
option  for  recovery  of  cardiac  function  postoperatively.  Lack 
of  analysis  on  various  factors  affecting  survival  rates  and 
small  sample  size  requires  further  studies  to  increase  greater 
confidence.  It  is  also  necessary  to  make  comparisons  of  the 
different  types  of  PCPS  and  clinical  results  of  using  them. 
Based  on  persistent  efforts  by  cardiothoracic  surgeons,  better 
clinical results will be reported, and a greater number of peo-
ple  may  be  have  their  lives  extended.     
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